中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (2): 77-80.

• 论著 •    下一篇

普萘洛尔治疗婴儿血管瘤复发因素分析

李丽1,徐子刚2,孙玉娟2,燕丽3,刘笑宇1,马琳1   

  1. 1. 首都医科大学附属北京儿童医院
    2. 北京首都医科大学附属北京儿童医院皮肤科
    3. 北京儿童医院皮肤科
  • 收稿日期:2016-04-05 修回日期:2016-06-05 出版日期:2017-02-15 发布日期:2017-01-24
  • 通讯作者: 马琳 E-mail:bch_maleen@aliyun.com
  • 基金资助:
    首都卫生发展科研专项基金;北京市属医院科研培育计划

Factors associated with the relapse of propranolol-treated infantile hemangioma

  • Received:2016-04-05 Revised:2016-06-05 Online:2017-02-15 Published:2017-01-24

摘要: 目的 了解口服普萘洛尔治疗婴儿血管瘤中导致复发的因素。方法 对235例口服普萘洛尔治疗且已经停用普萘洛尔6个月的血管瘤患儿复发因素进行调查,使用单因素和多因素非条件logistic回归模型进行分析。结果 235例患儿停药6个月内复发66例,复发率28.1%(66/235),其中15例属于严重复发,占复发病例的22.7%(15/66)。复发的危险因素包括服药剂量为1.5 mg·kg?1·d?1(OR = 3.566,95% CI:1.306 ~ 9.739),首次服药时年龄>8周(OR = 5.043,95% CI:1.248 ~ 20.376),服药疗程 ≤ 6个月(OR = 17.661,95% CI:4.899 ~ 63.665),停药时年龄<1岁(OR = 6.089,95% CI:1.835 ~ 20.204)。结论 影响普萘洛尔治疗婴儿血管瘤复发的危险因素较多,应针对这些危险因素采取措施,降低复发率。

关键词: 因素分析, 统计学

Abstract: Li Li, Xu Zigang, Sun Yujuan, Yan Li, Liu Xiaoyu, Ma Lin Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China Corresponding author: Ma Lin, Email: bch_maleen@aliyun.com 【Abstract】 Objective To analyze factors associated with the relapse of propranolol-treated infantile hemangioma. Methods The clinical data were collected from 235 children with infantile hemangioma who had discontinued propranolol for 6 months, and retrospectively analyzed. Factors for the relapse of propranolol-treated infantile hemangioma were analyzed by univariate and multivariate uncon-ditional logistic regression analyses. Results Of 235 patients followed for 6 months after drug withdrawal, 66 (28.1%) were identified to have recurrence of infantile hemangioma, of whom, 15 (22.7%) had severe recurrence. The risk of recurrence was significantly increased in patients taking propranolol at a daily dosage of 1.5 mg/kg compared with those taking propranolol at a daily dosage of 2 mg/kg (OR = 3.566, 95% CI: 1.306 - 9.739), in patients aged > 8 weeks at the initial drug treatment compared with those aged ≤ 8 weeks at the initial drug treatment (OR = 5.043, 95% CI: 1.248 - 20.376), in patients with the course of medication ≤ 6 months compared with those with the course of medication > 6 months (OR = 17.661, 95% CI: 4.899 - 63.665), as well as in patients aged < 1 year at drug withdrawal compared with those aged ≥ 1 year at drug withdrawal (OR = 6.089, 95% CI: 1.835 - 20.204). Conclusion There are many risk factors associated with the relapse of propranolol-treated infantile hemangioma, so some measures aimed at these risk factors should be taken to reduce the recurrence rate.